Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Immunoassay Interference Blocker Market is likely to Expand at a CAGR of ~ 7% During 2019-2029 - PMR


News provided by

Persistence Market Research Pvt. Ltd.

22 Jul, 2019, 10:30 GMT

Share this article

Share toX

Share this article

Share toX

NEW YORK, July 22, 2019 /PRNewswire/ -- The rapidly increasing prevalence of chronic diseases and the growth of the aging population across the world are among factors that are expected to increase the need for biochemical testing for the management of chronic diseases. The global increase in aging population is expected to increase the demand for diagnostic kits and reagents for the detection of age-related as well as other chronic conditions, which is expected to boost the immunoassay interference blocker market.

Continue Reading
This image opens in the lightbox
Persistence_Market_Research

According to latest research by PMR, the global immunoassay interference blocker market is estimated to have accounted for ~ US$ 200.0 Mn in terms of value in 2018. The report on the immunoassay interference blocker market further projects that the immunoassay interference blocker market is likely to expand at a CAGR of ~ 7% during the period 2019-2029.

Highly Dynamic Competition in the Global Landscape

The immunoassay interference blocker market is expanding in tandem with the growth of technology. Companies are channelizing efforts to maximize productivity, flexibility, and throughput capabilities, as well as redefine the productivity of their staff. Increase in product consolidation activities, which include sales and service agreements, collaborations, rising research & development activities, new product launches, joint ventures, partnerships, patent transfers, and mergers & acquisitions among global and regional players, are among the characteristics of the overall competition in the global immunoassay interference blocker market.

Get PDF Brochure for Research Insights at: https://www.persistencemarketresearch.com/samples/24343

The number of organizations involved in the immunoassay interference blocker market has increased during the past few years. The market of immunoassay interference blockers has been based on established NAT technologies and immunoassays. Although the NAT market continues to be managed by Roche, Thermo Fisher Scientific, and Bio-Rad Laboratories, Inc., many other biotechnology corporations have recently acquired significant IP property in this area.

The antibody interference blockers segment is a prominent revenue segment by product type in the immunoassay interference blocker market, which accounted for a revenue share of ~ 55.0% 2018. The antibody interference blockers segment is followed by the detection interference blockers that also generated significant revenue in the immunoassay interference blocker market.

Need more information about Report Methodology? Ask here:  https://www.persistencemarketresearch.com/methodology/24343

North America Accounts for 30% Shares in Revenues

Among all the end-use segments of the immunoassay interference blocker market, the academic and research institutes segment is projected to be leading segment, followed by the biotechnology companies segment. Academic and research institutes, followed by biotechnology companies, has emerged as a prominent consumer base, characterized by untapped product segments for immunoassay interference blocker to obtain high performance quality of immunoassay. This has encouraged the manufacturers of immunoassay interference blockers to capitalize on emerging latent opportunities. Companies are optimistic with regards to increasing molecular diagnosis and growth in the demand for immunoassay-based diagnostic products around the world, especially in North American countries.

Request For Full Report Access: https://www.persistencemarketresearch.com/checkout/24343

North America, followed by Europe and East Asia, is a leading region in the global immunoassay interference blocker market. The North America immunoassay interference blocker market accounted for a revenue share of ~ 30.0% in 2018. It was followed by the Europe market, which registered a significant revenue share and is estimated to register a CAGR of ~ 6.0% during the forecast period. Europe was followed by the East Asia and South Asia immunoassay interference blocker markets. Brazil, India, and China are among the emerging markets in the immunoassay interference blocker market. India is likely to be the fast-growing market in the global immunoassay interference blocker market, and is projected to grow at a CAGR of ~ 7.0% during the forecast period of 2019-2029.

The immunoassay interference blocker market report tracks some of the key companies operating in the immunoassay interference blocker market, such as Abcam plc, AMS Biotechnology (Europe) Limited, Aviva Systems Biology Corporation, Bio-Rad Laboratories, Inc., Meridian Bioscience, Inc., Roche Diagnostics GmbH, Rockland Immunochemicals, Inc., Scantibodies Laboratory, Inc., Thermo Fisher Scientific, and others. Majority of the domestic key players in the immunoassay interference blocker market are focused on expanding their product reach and enhancing their connectivity with the regional distributors of immunoassay interference blockers. The manufacturers of immunoassay interference blockers are expanding their business in opportunistic markets, which include India, Brazil, and China by expanding their sales channels across these countries.

Browse Research Release at @ https://www.persistencemarketresearch.com/market-research/immunoassay-interference-blocker-market.asp

Browse More:  Life Sciences & Transformational Health Research Reports

Popular Research Reports by PMR:

  • External Fixators Market : https://www.persistencemarketresearch.com/market-research/external-fixators-market.asp
  • Wearable Injectors Market : https://www.persistencemarketresearch.com/market-research/wearable-injectors-market.asp
  • Neuropathic Pain Market : https://www.persistencemarketresearch.com/market-research/neuropathic-pain-market.asp

Persistence Market Research Overview:

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Contact

Rohit Bhisey
Persistence Market Research
U.S. Sales Office:
305 Broadway, 7th Floor
New York City, NY 10007
+1-646-568-7751
United States
USA - Canada Toll-Free: 800-961-0353
Web Site: https://www.persistencemarketresearch.com 
Email: sales@persistencemarketresearch.com

Logo: https://mma.prnewswire.com/media/661339/Persistence_Market_Research.jpg

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.